Date: 2016-03-03
Type of information: R&D agreement
Compound:
Company: Merck KGaA (Germany) the European Molecular Biology Laboratory (EMBL) (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: R&D collaboration
Action mechanism:
Disease:
Details: * On March 3, 2016, Merck KGaA announced that it has entered into a research collaboration focused on cancer metabolism with the European Molecular Biology Laboratory (EMBL). The collaboration with EMBL is well-aligned with Merck’s research and development (R&D) strategy in biopharma to complement its capabilities in early-stage oncology research with external innovation – particularly in specific modalities, including cancer metabolism.
The aim of the collaboration is to investigate mechanisms by which cancer cells generate energy and growth-enabling building blocks, which could ultimately deliver novel therapeutic targets, as well as biomarkers. The collaboration partners will make use of EMBL’s extended capacities and capabilities in the area of metabolomics.
During the three-year collaboration, EMBL will apply its unique expertise, combining modelling and bioinformatics with experimental approaches to uncover these metabolic pathways and shed light on their control mechanisms. EMBL will also utilize the cutting-edge equipment of its Genomics and Metabolomics Core Facilities to resolve the transcriptional and metabolic profiles of the samples for the study.
Financial terms:
Latest news:
